8-K: Regen Biopharma Reports Unaudited Fiscal Year 2024 Results, Cites Ongoing Development of Regenerative Medical Applications

Regen Biopharma's unaudited financial statements for the fiscal year ended September 30, 2024, reveal a net loss of $867,252 and ongoing efforts in developing regenerative medical applications.

Summary

• Regen Biopharma, Inc. has released its unaudited consolidated financial statements for the fiscal year ending September 30, 2024.
• The company reported total revenues of $236,560, which includes $126,560 in revenues and $110,000 in related party revenues.
• Total costs and expenses amounted to $654,749, resulting in an operating loss of $418,189.
• The company's net loss for the year was $867,252, or $0.21 per share.
• The company's total assets were $177,611, while total liabilities reached $5,371,640.
• Stockholders' equity showed a deficit of $5,194,029.
• The company is focused on developing regenerative medical applications, with plans to license or sell these applications after Phase I or II clinical trials.
• Regen Biopharma is also actively identifying small molecules for oncology and autoimmune disease applications.
• The company has a going concern risk due to accumulated losses of $20,616,114 since inception.
• The company has an equity line agreement with Coventry Enterprises LLC for up to $10,000,000 in financing.

Sentiment

Score: 3

Explanation: The document reveals significant financial losses, a substantial accumulated deficit, and a going concern risk, which are major negative indicators. While the company is pursuing promising research, the financial situation is concerning.

Positives

• The company is actively pursuing the development of regenerative medical applications.
• Regen Biopharma has an equity line agreement in place to provide potential funding.
• The company is exploring small molecules for oncology and autoimmune disease treatments.

Negatives

• The company reported a significant net loss of $867,252 for the fiscal year 2024.
• Regen Biopharma has a substantial accumulated deficit of $20,616,114 since inception.
• The company's liabilities significantly outweigh its assets, with a total liability of $5,371,640 and a total asset of $177,611.
• The company has a going concern risk due to its financial losses.
• The company has a derivative liability of $1,397,274 related to convertible notes.

Risks

• The company's ability to continue as a going concern is dependent on obtaining additional financing and achieving profitability.
• There is no assurance that the company will be able to sell or license any of its products or that such sales or licenses will be on favorable terms.
• The company is in the early stages of development and requires FDA approval to market its products.
• The company has a significant amount of debt, including convertible notes payable.
• The company's net operating loss carryforwards may be subject to limitations under the Internal Revenue Code.

Future Outlook

The company plans to continue developing regenerative medical applications and intends to license or sell these applications after Phase I or II clinical trials, or alternatively, advance them to Phase III clinical trials. The company also plans to continue identifying small molecules for oncology and autoimmune disease applications.

Industry Context

Regen Biopharma operates in the biotechnology sector, specifically focusing on regenerative medicine. This sector is characterized by high research and development costs, long development timelines, and regulatory hurdles. The company's focus on licensing or selling its applications after Phase I or II trials is a common strategy to mitigate risk and generate revenue.

Comparison to Industry Standards

• Regen Biopharma's financial results are not directly comparable to large, established pharmaceutical companies due to its early stage of development.
• Companies like CRISPR Therapeutics and Editas Medicine, which are also in the gene editing and regenerative medicine space, often have significant research and development expenses and may not be profitable in their early stages.
• Regen's reliance on equity financing and convertible debt is common for early-stage biotech companies, but the high level of debt and accumulated losses are concerning.
• The company's strategy of licensing or selling after Phase I or II trials is similar to other biotech firms that seek to monetize their intellectual property early.
• The derivative liability related to convertible notes is a common issue for companies that use this type of financing, and the valuation of these liabilities can be complex.

Related Party Transactions

• The company has a licensing agreement with Zander Therapeutics, Inc., which is under common control.
• The company has notes payable to David Koos and Zander Therapeutics, Inc., both related parties.
• The company subleases office space from BST Partners, which is controlled by David Koos.
• The company has investment securities in Zander Therapeutics, Inc.

Stakeholder Impact

• Shareholders are impacted by the significant net loss and accumulated deficit.
• Employees are impacted by the company's going concern risk.
• Creditors are impacted by the company's high level of debt.
• Customers and suppliers are impacted by the company's early stage of development and reliance on future financing.

Next Steps

• The company will continue to develop regenerative medical applications.
• The company will seek to license or sell developed applications after Phase I or II clinical trials.
• The company will continue to identify small molecules for oncology and autoimmune disease applications.
• The company will continue to utilize the equity line agreement with Coventry Enterprises LLC for financing.

Key Dates

Keywords

Regen Biopharma, regenerative medicine, financial results, unaudited, biotechnology, clinical trials, equity financing, convertible notes, NR2F6, oncology, autoimmune disease